Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight

NCT07738614 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07738614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07738614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Recruiting
Start date
July 31, 2026
Completion date
December 31, 2026
Enrollment
56 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight